Neuren Pharmaceuticals (ASX:NEU) has said it’s received a “positive” response from the FDA regarding a potential approval for its Phase 3 trial to treat children with Phelan-McDermid Syndrome (PMS.) Using Neuren’s in-house drug candidate of interest, NNZ-2591, the company and the FDA have agreed a Phase 3 trial would be a single randomised double-blind and placebo-controlled 13 week trial looking at children aged 3-12 presenting with PMS. The company believes its current plans for Phase 3 testing would be more streamline than Phase 2 with a “less burdensome safety monitoring plan” appearing to…